ArticleLancet regional health. Americas2026
Development and validation of a miRNA-based prognostic model for high-grade serous ovarian cancer: a retrospective cohort study.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian cancer, particularly high-grade serous ovarian cancer (HGSOC), is the most lethal gynecological malignancy, mainly due to late-stage diagnosis and limited prognostic biomarkers. Current clinical markers, such as CA125, have limited prognostic accuracy for risk stratification. MicroRNAs (miRNAs) have emerged as promising biomarkers due to roles in tumor biology and stability in biofluids. This study aimed to identify and validate prognostic miRNA biomarkers in HGSOC. Methods: A machine learning pipeline was implemented to develop a prognostic model using miRNA data. Candidate miRNAs were identified through feature selection and differential expression analyses. Recursive Feature Elimination determined the optimal predictor set among miRNAs combined with age, stage, and Findings: The final model, incorporating 9 miRNAs with clinical variables, achieved an AUC of 0.762 [95% CI: 0.621-0.903], exceeding previously reported signatures. Key miRNAs, including hsa-miR-205-5p and hsa-miR-150-5p, were associated with angiogenesis, invasion, and chemoresistance pathways. In RT-qPCR validation, discriminative performance decreased; however, the continuous risk score remained independently associated with survival, achieving a C-index of 0.85 in multivariable analysis. Interpretation: We present an interpretable miRNA-based prognostic model for HGSOC integrating molecular features. Although ROC-based discrimination was limited in external validation, survival analyses supported independent prognostic value, with the continuous risk score significantly associated with survival. Continuous and classification-based stratification identified survival groups, supporting clinical relevance of the model and identified miRNA signature. Funding: CNPq; FAPERJ; Brazilian Ministry of Health (INCA/MS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.